Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab for CD19+ Mixed Phenotype Acute Leukemia (MPAL)
NCT04827745Phase 2Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Jun 2021
- Primary completion
- May 2025
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in mixed phenotype acute leukemia (MPAL), sponsored by University of Maryland, Baltimore. Started Jun 2021; status: completed.
02
Drugs
blinatumomab
03
Conditions
mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT04827745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04827745.